242,819 Shares in Geron Co. (NASDAQ:GERN) Acquired by Intech Investment Management LLC

Intech Investment Management LLC bought a new position in Geron Co. (NASDAQ:GERN) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 242,819 shares of the biopharmaceutical company’s stock, valued at approximately $1,102,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Arizona State Retirement System boosted its stake in Geron by 3.1% during the second quarter. Arizona State Retirement System now owns 115,400 shares of the biopharmaceutical company’s stock valued at $489,000 after buying an additional 3,465 shares in the last quarter. Values First Advisors Inc. boosted its position in shares of Geron by 13.6% during the 3rd quarter. Values First Advisors Inc. now owns 30,674 shares of the biopharmaceutical company’s stock valued at $139,000 after purchasing an additional 3,668 shares in the last quarter. CIBC Asset Management Inc grew its stake in shares of Geron by 32.7% in the 2nd quarter. CIBC Asset Management Inc now owns 15,438 shares of the biopharmaceutical company’s stock worth $65,000 after purchasing an additional 3,805 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Geron by 23.1% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 21,802 shares of the biopharmaceutical company’s stock worth $100,000 after purchasing an additional 4,094 shares in the last quarter. Finally, SG Americas Securities LLC lifted its stake in Geron by 32.6% during the third quarter. SG Americas Securities LLC now owns 22,630 shares of the biopharmaceutical company’s stock valued at $103,000 after purchasing an additional 5,559 shares during the last quarter. 73.71% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. Wedbush restated an “outperform” rating and issued a $8.00 price target on shares of Geron in a research report on Thursday, August 8th. StockNews.com raised shares of Geron to a “sell” rating in a research report on Monday, August 5th. Needham & Company LLC reaffirmed a “buy” rating and set a $6.00 price objective on shares of Geron in a research report on Friday, August 9th. HC Wainwright started coverage on shares of Geron in a research report on Tuesday, November 5th. They issued a “buy” rating and a $8.00 target price for the company. Finally, Leerink Partnrs raised Geron to a “strong-buy” rating in a research report on Monday, September 9th. One analyst has rated the stock with a sell rating, one has issued a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Geron has an average rating of “Moderate Buy” and a consensus price target of $7.05.

Geron Price Performance

Shares of GERN stock opened at $4.17 on Thursday. The firm has a market capitalization of $2.52 billion, a price-to-earnings ratio of -12.69 and a beta of 0.52. Geron Co. has a 12-month low of $1.64 and a 12-month high of $5.34. The company has a quick ratio of 2.74, a current ratio of 2.89 and a debt-to-equity ratio of 0.04. The firm has a fifty day moving average of $4.19 and a 200-day moving average of $4.32.

Geron (NASDAQ:GERN) last released its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.05. The business had revenue of $28.27 million for the quarter, compared to analysts’ expectations of $18.97 million. Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. Geron’s revenue for the quarter was up 17138.4% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.08) EPS. On average, equities research analysts forecast that Geron Co. will post -0.25 earnings per share for the current year.

Geron Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.